Skip Navigation


JAC Advance Access originally published online on April 28, 2009
Journal of Antimicrobial Chemotherapy 2009 64(1):62-68; doi:10.1093/jac/dkp137
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/1/62    most recent
dkp137v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Granieri, L.
Right arrow Articles by Merten, C. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granieri, L.
Right arrow Articles by Merten, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

A competition-based assay for the screening of species-specific antibiotics

Lucia Granieri1,2, Oliver J. Miller1,2, Andrew D. Griffiths1,2 and Christoph A. Merten1,2,*

1 Institut de Science et d’Ingénierie Supramoléculaires, Université de Strasbourg, 8 allée Gaspard Monge, 67083 Strasbourg Cedex, France 2 CNRS UMR 7006, 8 allée Gaspard Monge, 67083 Strasbourg Cedex, France

Received 18 February 2009; returned 13 March 2009; revised 20 March 2009; accepted 21 March 2009

* Corresponding author. ISIS—Biologie Chimique, 8 allée Gaspard Monge, BP70028, F-67083 Strasbourg Cedex, France. Tel: +33-3902-45173; Fax: +33-3902-45115; E-mail: cmerten{at}isis.u-strasbg.fr

Objectives: To develop a high throughput screening-compatible assay for the selection of species-specific antibiotics that do not harm human cells.

Methods: Staphylococcus aureus and human reporter cells continuously generating a fluorescence signal were competitively co-cultivated. The fluorescence signals were determined in the presence and absence of the specific antibiotic streptomycin and the toxic compound sodium azide. The results were compared with a standard cfu assay.

Results: In the absence of an effective antibiotic, S. aureus outgrew the human reporter cells and thus abolished the fluorescence signal. Conversely, the addition of streptomycin resulted in the growth of the reporter cells and a strong fluorescence signal. When sodium azide was added instead of streptomycin, only a very low background signal was obtained indicating toxicity and damage to the human reporter cells. The assay proved to be highly reliable (Z-factor >0.9) and high fluorescence signals correctly correlated with the efficient inhibition of S. aureus, as determined in comparative cfu assays.

Conclusions: In contrast to conventional cfu assays, the co-cultivation system allows the effects of a drug candidate on pathogens and human cells to be monitored simultaneously. Cytotoxic compounds can, therefore, be quickly ruled out during a primary screen. The nature of the screen also enables effective antibiotics to be identified without engineering the target pathogen to yield a fluorescence signal.

Keywords: Staphylococcus aureus , high-throughput assays , drug development , staphylococci , cytotoxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.